Clinical Trial Update: Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia [Phase 1]

View source ↗

Summary

Phase 1 safety, pharmacokinetics and pharmacodynamics study of a recombinant Factor VIIa variant (813d) in adults with Hemophilia A has completed and results we…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Recombinant Factor VIIa Variant 813d (Factor VIIa variant 813d)

Snippet

Sponsor: Catalyst Biosciences | Conditions: Hemophilia A | Phase 1 | Status: COMPLETED | Results posted: 2017-04-06